Thera-SAbDab

GEVOKIZUMAB

>   Structural Summary
TherapeuticGevokizumab
TargetIL1B
Heavy ChainQVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS
Light ChainDIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK
100% seqID Fv Structure4g6k [Fvs: HL], 4g6m [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedIRIS, National Eye Institute, North Shore-Long Island Jewish Health System, Novartis, Servier, University of Zurich, XOMA
Conditions Approvedna
Conditions ActiveUveitis, Acne vulgaris, Acute coronary syndromes, Diabetic nephropathies, Giant cell arteritis, Labyrinthitis, Myositis, Osteoarthritis, Schnitzler syndrome, Scleritis, Colorectal cancer, Renal cell carcinoma
Conditions DiscontinuedRheumatoid arthritis, Cancer, Gout, Juvenile rheumatoid arthritis, Type 1 diabetes mellitus, Type 2 diabetes mellitus, Pyoderma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]